XML 15 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net income (loss) $ 7,529 $ (185,465)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 9,402 10,083
Share-based compensation 10,309 12,716
Non-cash royalty revenue (77,535) (75,006)
Non-cash interest expense 38,666 97,459
Loss on disposal of assets, net 936 18
Gain from deconsolidation of MiNK Therapeutics, Inc. (100,924) 0
Unrealized loss on long-term investments 20,096 1,103
Gain on lease terminations 0 (5,334)
Other, net (200) (3,741)
Changes in operating assets and liabilities:    
Accounts receivable (49) 25,613
Prepaid expenses 1,160 5,751
Accounts payable 26,840 (13,682)
Deferred revenue 1 (7)
Accrued liabilities and other current liabilities 13,435 1,722
Other operating assets and liabilities (10,243) (893)
Net cash used in operating activities (60,577) (129,663)
Cash flows from investing activities:    
Purchases of plant and equipment (6) (503)
Proceeds from sale of plant and equipment 358 24
Proceeds from sale of long-term investment 62 527
Net cash provided by investing activities 414 48
Cash flows from financing activities:    
Net proceeds from sale of equity 27,525 25,937
Net proceeds from sale of subsidiary shares in private placement 0 5,800
Proceeds from Ligand Purchase Agreement, net of expenses 0 73,851
Proceeds from employee stock purchases and option exercises 122 648
Proceeds from the issuance of long-term debt, net 2,500 0
Impact to cash resulting from deconsolidation of a subsidiary (1,682) 0
Purchase of treasury shares to satisfy tax withholdings (87) 0
Payment of long-term debt (2,500) 0
Payment of finance lease obligation (4,659) (7,766)
Net cash provided by financing activities 21,219 98,470
Effect of exchange rate changes on cash 43 (216)
Net decrease in cash, cash equivalents and restricted cash (38,901) (31,361)
Cash, cash equivalents and restricted cash, beginning of period 44,071 79,779
Cash, cash equivalents and restricted cash, end of period 5,170 48,418
Supplemental cash flow information:    
Cash paid for interest 903 1,737
Supplemental disclosures - non-cash activities:    
Insurance financing agreement 552 771
Issuance of stock options for payment of certain employee bonuses 0 9,321
Lease right-of-use assets obtained in exchange for new operating lease liabilities 107 105
Lease right-of-use assets obtained in exchange for new finance lease liabilities 10,737 122
Employee Bonus [Member]    
Supplemental disclosures - non-cash activities:    
Issuance of common stock 3,964 0
Issuance of subsidiary stock options for payment of certain employee bonuses $ 0 $ 1,032